National Cancer Institute
U.S. National Institutes of Health |

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
About NCI
NCI Drug Dictionary
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Información en español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

panitumumabPatient Information
A human monoclonal antibody produced in transgenic mice that attaches to the transmembrane epidermal growth factor (EGF) receptor. Panitumumab may inhibit autocrine EGF stimulation of tumor cells that express the EGF receptor, thereby inhibiting tumor cell proliferation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:clone E7.6.3
monoclonal antibody ABX-EGF
US brand name:Vectibix
Abbreviation:MOAB ABX-EGF
Code name:ABX-EGF

Previous:pamidronate disodium, pan HER/VEGFR2 receptor tyrosine kinase inhibitor BMS-690154, pan-AKT kinase inhibitor GSK690693, Panglobulin, Panhematin
Next:panobinostat, Panretin, PANVAC-F, PANVAC-V, Panwarfin

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health